Antithrombotic therapy after transcatheter aortic valve implantation: a new piece of the still unresolved puzzle

The 2017 marks the 40^th anniversary of percutaneous coronary intervention (PCI), but also the 15^th anniversary for transcatheter aortic valve implantation (TAVI) (1). For more than 50 years, surgical aortic valve replacement (SAVR) has been the standard of care for patients with severe symptomatic aortic stenosis, improving outcomes and prolonging the lives of these patients. In 1990s the transcatheter delivery of a bioprosthetic aortic valve was conceptualized and largely tested in animals.